Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22725608
Doll C, et al. (2012) Deciphering ยต-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol 167, 1259-70 22725608
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T370-p - MOR-1 (mouse)
Modsite: sARIRQNtREHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), brain
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
PHOSPHATASE PPP1CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
morphine no change compared to control
siRNA DAMGO inhibit treatment-induced increase GRK2 siRNA
siRNA DAMGO inhibit treatment-induced increase GRK3 siRNA
DAMGO GRK6 (human) no effect upon treatment-induced increase GRK6 siRNA has no effect
siRNA increase PP1G siRNA
Downstream Regulation
Effect of modification (function):  receptor internalization, induced

S375-p - MOR-1 (mouse)
Modsite: QNtREHPstANtVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), brain
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
PHOSPHATASE PPP1CA (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE GRK3 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme
KINASE GRK5 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
morphine increase
siRNA DAMGO inhibit treatment-induced increase GRK2 siRNA
siRNA DAMGO inhibit treatment-induced increase GRK3 siRNA
DAMGO GRK6 (human) no effect upon treatment-induced increase GRK6 siRNA has no effect
siRNA morphine inhibit treatment-induced increase GRK5 siRNA
morphine GRK6 (human) no effect upon treatment-induced increase GRK6 siRNA has no effect
siRNA morphine inhibit treatment-induced increase GRK2 siRNA partially inhibits
siRNA morphine inhibit treatment-induced increase GRK3 siRNA partially inhibits
etonitazene increase
calyculin_A increase
okadaic_acid no change compared to control
siRNA increase PP1G siRNA
Downstream Regulation
Effect of modification (function):  receptor internalization, induced